# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volunteers and Participants With Narcolepsy

> **NCT03748979** · PHASE1 · COMPLETED · sponsor: **Takeda** · enrollment: 57 (actual)

## Conditions studied

- Healthy Participants
- Narcolepsy

## Interventions

- **DRUG:** TAK-925
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03748979
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-21
- **Primary completion:** 2019-10-24
- **Final completion:** 2019-10-24
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2020-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03748979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03748979, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volunteers and Participants With Narcolepsy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03748979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*